Allergy Therapeutics PLC Directorate changes (2053H)
June 06 2017 - 2:01AM
UK Regulatory
TIDMAGY
RNS Number : 2053H
Allergy Therapeutics PLC
06 June 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Directorate changes
6 June 2017 Allergy Therapeutics (AIM:AGY), the fully integrated
speciality pharmaceutical company specialising in allergy vaccines,
announces the appointment of Dr Tunde Otulana to its Board of
Directors as a Non-Executive Director with effect from 6 June
2017.
Additionally, Dr Thomas Lander has indicated that he wishes to
retire from his position as a Non-Executive Director of the Group
with effect from 30 June 2017.
Dr Babatunde 'Tunde' Adekunle Otulana, aged 60, brings over 20
years' pharmaceutical industry knowledge and significant executive
level experience in clinical development and medical affairs roles.
He currently serves as Senior Vice President and Chief Medical
Officer at Mallinckrodt Pharmaceuticals where he has responsibility
for all global medical functions, and has previously worked for
Boehringer Ingelheim Pharmaceutical Inc. as Senior Vice President,
Clinical Development and Medical Affairs. He has previously spent
over six years working at the US Food and Drug Administration (FDA)
as a Medical Officer and Medical Team Leader in the Division of
Pulmonary-Allergy Drug Products.
Dr Otulana received his medical degree in Nigeria where he also
completed hospital residency training. He then moved to Cambridge,
UK to complete his Clinical Research Fellowship in Pulmonary
Medicine at the Papworth and Addenbrooke's hospitals, University of
Cambridge.
Peter Jensen, Chairman of Allergy Therapeutics, commented: "We
are pleased to welcome Tunde to the Board. He brings a wealth of
global experience in clinical and regulatory work, particularly
with the FDA in the United States, which will be especially
valuable as we continue to execute our global strategy.
"I also want to take this opportunity to thank Thomas for his
significant contribution and support to the Group during the past
five years. Thomas has always given the Board very clear advice on
R&D matters and his experience has been hugely valuable. We all
wish him well for the future in his retirement."
Allergy Therapeutics confirms that there are no further
disclosures to be made in relation to Rule 17 of paragraph (g) of
Schedule Two of the AIM Rules for Companies in respect of Dr
Otulana's appointment.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Group sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Group employs c.495 employees and is listed on the
London Stock Exchange (AIM:AGY). For more information, please see
www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEAEKSEDFXEAF
(END) Dow Jones Newswires
June 06, 2017 02:01 ET (06:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024